Recently, the National Medical Products Administration officially approved the marketing of Evocalcet (approval date: December 30, 2025).

Evocalcet are primarily used to treat secondary hyperparathyroidism (SHPT) caused by long-term dialysis in patients with chronic kidney disease (CKD). SHPT is a common complication in CKD patients that can lead to multisystem complications affecting the bones, cardiovascular and cerebrovascular systems, and skin, significantly impacting patients’ quality of life and long-term survival. As a second-generation calcimimetic, Ivocase Tablets not only effectively reduce parathyroid hormone (PTH), serum calcium, and FGF23 levels but also lower serum phosphorus by inhibiting bone resorption. With higher bioavailability and a lower incidence of gastrointestinal adverse reactions, it offers a superior clinical treatment option. The approval and launch of this product will further enrich the company’s product pipeline and enhance its market competitiveness.

The successful launch of this product marks a further expansion of Kvvit’s product pipeline in the field of kidney disease treatment and demonstrates the company’s comprehensive capabilities in the research, development, and commercialization of complex generic drugs. Kvvit remains committed to addressing clinical needs and is dedicated to providing patients with accessible, high-quality pharmaceutical solutions.

Currently, Kvvit is actively advancing production preparations, supply chain optimization, and market access efforts for this product, with the aim of ensuring a stable supply and making it available to patients as soon as possible.